S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
NASDAQ:KRBP

Kiromic BioPharma (KRBP) Stock Price, News & Analysis

$3.00
+0.23 (+8.30%)
(As of 03:19 PM ET)
Today's Range
$2.97
$3.04
50-Day Range
$1.25
$3.46
52-Week Range
$0.16
$8.97
Volume
5,519 shs
Average Volume
9,366 shs
Market Capitalization
$3.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KRBP stock logo

About Kiromic BioPharma Stock (NASDAQ:KRBP)

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

KRBP Stock Price History

KRBP Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Kiromic BioPharma Announces Uplisting to OTCQB Market
Kiromic BioPharma Inc Ordinary Shares
Staidson Beijing Biopharma (300204)
KRBP - Kiromic BioPharma, Inc.
Kiromic BioPharma Announces Reverse Stock Split
See More Headlines
Receive KRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
3/28/2024
Next Earnings (Estimated)
4/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:KRBP
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Net Income
$-20,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($7.25) per share

Miscellaneous

Free Float
1,246,000
Market Cap
$3.57 million
Optionable
Not Optionable
Beta
1.99
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Pietro Bersani CPA (Age 56)
    J.D., CEO & Director
    Comp: $546.76k
  • Dr. Scott Dahlbeck M.D. (Age 62)
    Pharm.D., PharmD, Chief of Staff
    Comp: $385.36k
  • Mr. Brian Hungerford (Age 49)
    CFO & Principal Accounting Officer
  • Dr. Leonardo Mirandola Ph.D. (Age 43)
    Chief Scientific Officer & Interim COO

KRBP Stock Analysis - Frequently Asked Questions

How have KRBP shares performed in 2024?

Kiromic BioPharma's stock was trading at $0.87 at the beginning of the year. Since then, KRBP shares have increased by 244.8% and is now trading at $3.00.
View the best growth stocks for 2024 here
.

When is Kiromic BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 15th 2024.
View our KRBP earnings forecast
.

How were Kiromic BioPharma's earnings last quarter?

Kiromic BioPharma, Inc. (NASDAQ:KRBP) issued its quarterly earnings data on Monday, March, 18th. The company reported ($4.16) earnings per share for the quarter.

When did Kiromic BioPharma's stock split?

Kiromic BioPharma's stock reverse split on Monday, March 13th 2023. The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Kiromic BioPharma IPO?

Kiromic BioPharma (KRBP) raised $16 million in an IPO on Friday, October 16th 2020. The company issued 1,200,000 shares at a price of $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Paulson Investment Company was co-manager.

How do I buy shares of Kiromic BioPharma?

Shares of KRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRBP) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners